Serotonin modulation of cerebral blood flow measured with positron emission tomography (PET) in humans

Synapse

Volumn 55, Issue 4, 2005, Pages 224-229

  Geday, Jacob ^a   Hermansen, Flemming ^a   Rosenberg, Raben ^a   Smith, Donald F ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antidepressant; Cerebral blood flow; Citalopram; Clomipramine; Positron emission tomography (PET); Selective serotonin reuptake inhibitor; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; PLACEBO; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; BRAIN BLOOD FLOW; CINGULATE GYRUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INFUSION; DRUG RECEPTOR BINDING; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPOTHALAMUS; IN VIVO STUDY; MALE; NAUSEA; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PULVINAR; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM; SIDE EFFECT; THALAMUS; THALAMUS DORSOMEDIAL NUCLEUS; THALAMUS LATERAL NUCLEUS; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA;

ADULT; AGED; BRAIN; CEREBRAL ARTERIES; CEREBROVASCULAR CIRCULATION; CITALOPRAM; CLOMIPRAMINE; DOUBLE-BLIND METHOD; FEMALE; GYRUS CINGULI; HUMANS; HYPOTHALAMUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OXYGEN RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; THALAMUS;

EID: 13844270803     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20112     Document Type: Article

References (57)

1. Anderson IM, Ware CJ, da-Roza DJ, Cowen PJ. 1992. Decreased 5-HT-mediated prolactin release in major depression. Br J Psychiatry 160:372-378.
2. Anonymous. 2001. Analyzing functional imaging studies. Editorial. Nat Neurosci 4:333.
3. Attenburrow MJ, Mitter PR, Whale R, Terao T, Cowen PJ. 2001. Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology (Berl) 155:323-326.
4. Bremner JD, Innis RB, Salomon RM, Staib LH, Ng CK, Miller HL, Bronen RA, Krystal JH, Duncan J, Rich D, Price LH, Malison R, Dey H, Soufer R, Charney DS. 1997. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 54:364-374.
5. Bremner JD, Vytnilingam M, Ng CK, Vermetten E, Nazeer A, Oren DA, Berman RM, Charney DS. 2003. Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. JAMA 289:3125-3134.
6. Brust P, Scheffel U, Szabo Z. 1999. Radioligands for the study of the 5-HT transporter in vivo. IDrugs 2:129-145.
7. Charlier C, Pinto E, Ansseau M, Plomteux G. 2000. Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol 15:453-459.
8. Charney DS. 1998. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 59(Suppl 14):11-14.
9. Collins DL, Neelin P, Peter TM, Evans AC. 1994. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr 18:192-205.
10. Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR, Charney DS. 1994. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 51:865-874.
11. Delgado PL, Moreno FA, Onate L, Gelenberg AJ. 2002. Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int J Neuropsychopharmacol 5:63-66.
12. Drevets WC, Raichle ME. 1992. Neuroanatomical circuits in depression: implications for treatment mechanisms. Psychopharmacol Bull 28:261-274.
13. Drevets WC, Bogers W, Raichle ME. 2002. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol 12:527-544.
14. Duvernoy HM, Bourgouin P, Cabanis A, Cattin F, Cuyot J, Iba-Zizen MT, Maeder P, Parratte B, Tatu L, Vuillier F. 1999. The human brain. Surface, three-dimensional sectional anatomy with MRI, and blood supply. Wien: Springer.
15. George MS, Ketter TA, Parekh PI, Horwitz B, Herscovitch P, Post RM. 1995. Brain activity during transient sadness and happiness in healthy women. Am J Psychiatry 152:341-351.
16. Gold S, Arndt S, Johnson D, O'Leary DS, Andreasen NC. 1997. Factors that influence effect size of 150 PET studies: a meta-analytic review. NeuroImage 5:280-291.
17. Golden RN, Hsiao J, Lane E, Hicks R, Rogers S, Potter WZ. 1989. The effects of intravenous clomipramine on neurohormones in normal subjects. J Clin Endocrinol Metab 68:632-637.
18. Golden RN, Ekstrom D, Brown TM, Ruegg R, Evans DL, Haggerty-JJ J, Garbutt JC, Pedersen CA, Mason GA, Browne J. 1992. Neuroendocrine effects of intravenous clomipramine in depressed patients and healthy subjects. Am J Psychiatry 149:1168-1175.
19. Gram LF. 1986. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group (DUAG). Psychopharmacology (Berl) 90:131-138.
20. Gram LF. 1999. Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG). Clin Pharmacol Ther 66:152-165.
21. Guelfi JD, Strub N, Loft H. 2000. Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial. J Affect Disord 58:201-209.
22. Gurevich EV, Joyce JN. 1996. Comparison of [3H]paroxetine and [3H]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain. Neuropsychopharmacology 14:309-323.
23. Haber S, McFarland NR. 2001. The place of the thalamus in frontal cortical-basal ganglia circuits. Neuroscientist 7:315-324.
24. Houle S, Ginovart N, Hussey D, Meyer JH, Wilson AA. 2000. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med 27:1719-1722.
25. Hyttel J. 1982. Citalopram-pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 6:277-295.
26. Johanssen P, Jakobsen J, Bruhn P, Gjedde A. 1999. Cortical responses to sustained and divided attention in Alzheimer's disease. NeuroImage 10:269-281.
27. Joubert AF, Sánchez C, Larsen F. 2000. Citalopram. Hum Psychopharmacol Clin Exp 15:439-451.
28. Kapitany T, Schindl M, Schindler SD, Hesselmann B, Fureder T, Barnas C, Sieghart W, Kasper S. 1999, The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res 88:75-88.
29. Kapur S, Meyer J, Wilson AA, Houle S, Brown GM. 1994. Modulation of cortical neuronal activity by a serotonergic agent: a PET study in humans. Brain Res 646:292-294.
30. Kasper S, Muller-Spahn F. 2002. Intravenous antidepressant treatment: focus on citalopram. Eur Arch Psychiatry Clin Neurosci 252:105-109.
31. Ketter TA, Kimbrell TA, George MS, Dunn RT, Speer AM, Benson BE, Willis MW, Danielson A, Frye MA, Herscovitch P, Post RM. 2001. Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Biol Psychiatry 49:97-109.
32. Kupfer DJ, Pollock BG, Perel JM, Jarrett DB, McEachran AB, Miewald JM. 1991. Immediate effects of intravenous clomipramine on sleep and sleep-related secretion in depressed patients. Psychiatry Res 36:279-289.
33. Lauritzen M. 2001. Relationship of spikes, synaptic activity, and local changes of cerebral blood flow. J Cereb Blood Flow Metab 21:1367-1383.
34. Lavoie B, Parent A. 1991. Serotoninergic innervation of the thalamus in the primate: an immunohistochemical study. J Comp Neurol 312:1-18.
35. Mann JJ, Malone KM, Diehl DJ, Perel J, Nichols TE, Mintun MA. 1996. Positron emission tomographic imaging of serotonin activation effects on prefrontal cortex in healthy volunteers. J Cereb Blood Flow Metab 16:418-426.
36. Mayberg HS. 1997. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 9:471-481.
37. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, Silva JA, McGinnis S, Glass TG, Martin CC, Fox PT. 1997. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 8:1057-1061.
38. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, Silva JA, Tekell JL, Martin CC, Lancaster JL, Fox PT. 1999. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 156:675-682.
39. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA. 2000. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 48:830-843.
40. Mega MS, Cummings JL. 1994. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 6:358-370.
41. Meyer JH, Kapur S, Wilson AA, DaSilva JN, Houle S, Brown GM. 1996. Neuromodulation of frontal and temporal cortex by intravenous d-fenfluramine: an [15O]H2O PET study in humans. Neurosci Lett 207:25-28.
42. Meyer JH, Kennedy S, Brown GM. 1998. No effect of depression on [(15)O]H2O PET response to intravenous d-fenfluramine. Am J Psychiatry 155:1241-1246.
43. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S. 2001. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 158:1843-1849.
44. Parent A, Descarries L, Beaudet A. 1981. Organization of ascending serotonin systems in the adult rat brain. A radioautographic study after intraventricular administration of [3H]5-hydroxytryptamine. Neuroscience 6:115-138.
45. Petersson KM, Nichols TE, Poline JB, Holmes AP. 1999. Statistical limitations in functional neuroimaging. I. Non-inferential methods and statistical models. Philos Trans R Soc Lond B 354:1239-1260.
46. Pollock BG, Perel JM, Nathan RS, Kupfer DJ. 1989. Acute antidepressant effect following pulse loading with intravenous and oral clomipramine. Arch Gen Psychiatry 46:29-35.
47. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. 2001. A default mode of brain function. Proc Natl Acad Sci U S A 98:676-682.
48. Reis M, Lundmark J, Bengtsson F. 2003. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther Drug Monit 25:183-191.
49. Sallee FR, Vrindavanam NS, Deas ND, Carson SW, Sethuraman G. 1997. Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial. Am J Psychiatry 154:668-673.
50. Seedat S, Warwick J, van Heerden B, Hugo C, Zungu-Dirwayi N, van Kradenburg J, Stein DJ. 2004. Single photon emission computed tomography in posttraumatic stress disorder before and after treatment with a selective serotonin reuptake inhibitor. J Affect Disord 80:45-53.
51. Seifritz E, Baumann P, Muller MJ, Annen O, Amey M, Hemmeter U, Hatzinger M, Chardon F, Holsboer-Trachsler E. 1996. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 14:253-263.
52. Seminowicz DA, Mayberg HS, McIntosh AR, Goldapple K, Kennedy S, Segal Z, Rafi-Tari S. 2004. Limbic-frontal circuitry in major depression: a path modeling metanalysis. Neuroimage 22:409-418.
53. Smith DF. 1999. Neuroimaging of serotonin uptake sites and antidepressant binding sites in the thalamus of humans and "higher" animals. Eur Neuropsychopharmacol 9:537-544.
54. Smith DF, Geday J. 2001. PET neuroimaging of clomipramine challenge in humans: focus on the thalamus. Brain Res 892:193-197.
55. Smith GS, Ma Y, Dhawan V, Gunduz H, Carbon M, Kirshner M, Larson J, Chaly T, Belakhleff A, Kramer E, Greenwald B, Kane JM, Laghrissi-Thode F, Pollock BG, Eidelber D. 2002. Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects. Synapse 45:105-112.
56. Talairach P, Tournoux P. 1988. Co-planar stereotaxic atlas of the human brain: 3-dimensional proportional system: an approach to cerebral imaging. Stuttgart: Georg Thieme.
57. Talbot PS, Lamelle M. 2002. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 12:503-511.